News
DESTINY-Breast02 trial: Trastuzumab deruxtecan after failure on TDM-1, An Update
Oncologyme
/ Apr 30, 2023
In the phase 3 DESTINY-Breast02 trial, #Trastuzumab deruxtecan (T-DXd) improved the PFS and OS in patients with HER2-positive metastatic breast...
After a median follow-up of 67.6 months, the 5-year EFS rate was 70.7% in the carboplatin arm vs 64.1% in the control arm (HR, 0.798; P = 0.081). In patients younger than 50 years, the 5-year EFS rate was 74.2% vs 61.7%, respectively (HR, 0.642; P = .004).
Oncologyme
/ Apr 30, 2023
On December 9, 2022, #FDA has approved #Atezolizumab for adult and pediatric unresectable or metastatic #alveolar soft part #sarcoma (ASPS). The...
RxPONDER PRO sub-study: Impact of chemotherapy on cognitive functions in patients with early breast cancer.
Oncologyme
/ Apr 30, 2023
In the #RxPONDER PRO sub-study presented by Dr. Irene Kang at the 2022 San Antonio Breast Cancer Symposium (SABCS) Annual...
CheckMate 914 trial: adjuvant Immunotherapy in Renal Cell Carcinoma
Oncologyme
/ Apr 30, 2023
In the phase 3 CheckMate 914 trial, Adjuvant #nivolumab plus #ipilimumab failed to improve the clinical outcomes in patients with...
New FDA approval for Pembrolizumab in the adjuvant treatment of NSCLC.
Oncologyme
/ Apr 30, 2023
On January 26, 2023, the #FDA has approved #pembrolizumab for adjuvant treatment of NSCLC patients following complete resection and platinum-based...
STIC CTC trial: the use of circulating tumor cell (CTC) to guide the treatment in metastatic breast cancer.
Oncologyme
/ Apr 30, 2023
In the phase 3 STIC CTC trial, overall survival (OS) was improved when circulating tumor cell (CTC) count was used...
PURE 01 trial: Neoadjuvant Pembrolizumab for Muscle-invasive Bladder Carcinoma
Oncologyme
/ Apr 30, 2023
In the phase II PURE-01 trial, #neoadjuvant #pembrolizumab has shown to improve the clinical outcomes in patients with muscle-invasive #bladder...
monarchE trial: Abemaciclib in the adjuvant setting of HR-positive breast cancer
Oncologyme
/ Apr 30, 2023
In the preplanned interim analysis of #monarchE trial, the addition of #abemaciclib to adjuvant endocrine therapy improved the invasive disease-free...
In a phase III Indian study, the addition of weekly carboplatin significantly improved overall survival and event-free survival when added to a taxane-anthracycline neoadjuvant chemotherapy regimen for patients with locally advanced triple-negative breast cancer.
Oncologyme
/ Apr 30, 2023
In the phase 2, PACE trial, the combination of #palbociclib plus fulvestrant did not improve significantly PFS compared with fulvestrant...
Neoadjuvant Carboplatin Shows Improved Survival in TNBC, Indian study
Apr 16, 2023
In a phase III Indian study, the addition of weekly carboplatin significantly improved overall survival and event-free survival when added...
.png)